Background: Diabetic macular edema (DME) is the main cause of visual impairment in diabetic retinopathy (DR). Current gold standard therapy of DME is macular laser photocoagulation (MPC). Growing evidences have shown benefits of intravitreal anti-VEGF agents (i.e bevacizumab) and intravitreal corticosteroids (i.e triamcinolone acetonide). Aim: To compare the visual acuity (VA) improvement of patients with DME, treated with intravitreal bevacizumab (IVB), a combination of IVB and intravitreal triamcinolone (IVB/IVT), and MPC. Method: A comprehensive PubMed® and Cochrane® databases search was conducted on May 4th, 2017 using appropriate keywords (diabetic macular edema, bevacizumab, triamcinolone, and laser photocoagulation using their MeSH terms). Studies were filtered using inclusion criterions (clinical trials, RCT, meta-analysis, systematic review, English, humans, and publication within 10 years) Results: Three studies (2 systematic reviews and 1 RCT) were found suitable. From these results, all studies showed favoring effects of IVB when compared to IVB/IVT combination and MPC in short term period (up to 6 months). However, there was no significant improvement of VA beyond this period in all groups. Conclusion: IVB appears to be superior to IVB/IVT and MPC in improving VA during 6 months followup period. Future systematic reviews and meta-analysis are required on the effect of IVB and MPC combination in cases of DME.
outheast Asia is facing an increasing burden of non-communicable diseases. One of the diseases that cost enormous financial and social burden is DM. Approximately 2.1% of deaths in Southeast Asia is caused by DM and its related complications. 1 Data in Indonesia shows that DM affects 4.8% of the population and is responsible for 3% of death in the country. One of the most devastating complications of DM is diabetic retinopathy (DR). DR affects approximately 30% of DM patients of productive age. Data in Indonesia showed varied prevalence of DR, from 17.2% -S LITERATURE RE VIEW 42.6% leading to lower quality of life and loss of productivity. 2 The main cause of visual impairment in DR is DME. DME is caused by the leakage of blood-retinal barrier (BRB) due to hyperglycemia. BRB disruption or so-called breakdown occurs due to loss of pericytes, loss of cell to cell junctions, and thickening of the basement membrane. This will lead to extravasation of fluid into the extracellular space thus formation of DME. These effects are usually mediated by VEGF which triggers neovascularization, triggers phosphorylation of proteins in the tight junction thus increasing permeability and triggers release of matrix metalloproteinases (MMPs) thus bridging the thickening of the basement membrane. 3 Inflammation also plays role in pathogenesis of visual impairment in DME by triggering retinal leukostasis. Inflammation leads to release of cytokines, prostaglandins, leukostasis, and accumulation of macrophages. Increased leukostasis in DR leads to impaired endothelial function, retinal blood supply, and vascular permeability. 3 The current gold standard of therapy in cases of DME is macular laser photocoagulation (MPC). However, studies have shown promising results of intravitreal anti-VEGF and intravitreal corticosteroids in cases of DME. Bevacizumab is one of the anti-VEGF drugs that is widely used as an off-label treatment for DME. Thus, this evidence-based case report would like to review the effectiveness of intravitreal anti-VEGF agent (bevacizumab/IVB), a combination of IVB and intravitreal corticosteroids (triamcinolone acetonide/IVT), and laser photocoagulation in the treatment of DME with the improvement of visual acuity as the primary outcome.
METHODS
A comprehensive search via Pubmed® and Cochrane® database were conducted using search terms "diabetic macular edema", "bevacizumab", "triamcinolone", "laser photocoagulation", and their MeSH terms on May 4 th , 2017. Results obtained were filtered by type of study (clinical trials, randomized controlled trials (RCT), systematic review, and meta-analysis), time of publication (10 years), language (English), and subjects (human). Further screening on titles and abstracts were performed to include relevant studies to our clinical question. From these selected articles, further full-text analysis was carried out. The process of the database search is as presented in Fig 1 . Studies obtained were appraised using tools from the Center of Evidence-Based Medicine, University of Oxford for systematic review and randomized controlled trials. 4 
RESULTS

Search results
From the search results filtered with inclusion criteria and passed the screening of titles and abstracts, 8 studies were found. From these 8 studies, there are few studies excluded from our appraisal and analysis. The studies which are dismissed along with the reasons are presented in Table 1 . Seven studies were obtained and full-text analysis was carried out. From these studies, 1 RCT and 2 systematic reviews.
Quality of studies
Studies used were appraised using tools from Oxford's Center for Evidence-Based Medicine based on the type of the study as presented in Table 2 Current gold standard therapy of DME is MPC. Growing evidences, such as studies by RISE, RIDE, BOLT and RESOLVE studies have shown the safety and efficacy of anti-VEGF agents. 13, 14, 15 From the selection of anti-VEFG agents, bevacizumab has shown increasing popularity and seems to be superior in terms of cost analysis. This report includes 3 studies with 2 systematic reviews (level of evidence 1) and 1 randomised controlled trials (level of evidence 2). All studies were appraised by authors and have shown good qualities. However, there are few limitations of the studies included such as small sample size per intervention group (all less than 100 participants) and the heterogeneity of the population by Goyal, et al. 11 From these studies, the DRCN study was excluded from our analysis as this study did not use a combination of IVB and IVT. 17 A study conducted by Ahmadieh, et al. also did not fulfill our inclusion criteria as they did not use MPC as treatment. 18 These studies also did not mention any interval dosing or use, if any, of MPC. Hence, we propose further additional information to be disclosed for future studies and appraisal.
These reports showed a consistent result of VA improvement in short term follow-up period of IVB use with varied follow-up period (maximum of 6 months). However, this effect seemed to deteriorate over long-term follow-up period as shown as study by Soehilian in the 2 year followup period. 12 The study by Soehilian, however, had high number of loss to followup, which might influence their result.
All the studies show a consistent result of ineffectiveness IVT use which did not show any additional improvement when compared to other two groups. Instead, studies show few cases of complications in the IVB/IVT group such as increase of IOP and one case of cataract. [10] [11] [12] An author discussed that this may be the reason of poor VA improvement when compared to other groups. 12 However, we seem to disagree on this as for the number of complications and increased IOP is seemed to be small when compared to the total sample size thus additional of IVT to the therapy regimen may not be beneficial. Another study by Sutter, et al. showed conflicting result to our study as they found improvement of BCVA post-injection of 4 mg IVT when compared to placebo. 19 An author proposed that this may due to the certain degree of macular ischemia. 20 Appropriate dosing of IVT should also be explored further as small dose (such as 2 mg used in our studies) may not produce beneficial effect but higher dose seem to produce more cases of ocular hypertension. 20 A study of cost-effective analysis showed that use of laser and anti-VEGF combination therapy produced better quality-adjusted life-years (QALY) when compared to other monotherapy and other combination therapy. Laser and anti-VEGF combination was also proven to be more effective in terms of cost. 21 At the lower cost of ranibizumab, bevacizumab had also been proven to be superior in terms of cost and QALY. However, Pershing, et al. seemed to point out questions on its safety regarding systemic absorption. 21 Future studies need to be conducted to to provide optimal dosing and intervals as well as looking at the effects of MPC and IVB combination.
We also included studies written in English only thus might affect our literature search. Studies available on this matter seem to originate mostly from Iran as bevacizumab may not be legal to be used in cases of DME in several countries, including the US.
CONCLUSION
IVB appears to be superior to IVB/IVT and MPC in improving VA during first 6 months follow-up period. Addition of IVT to the treatment of DME may not provide additional benefit. Future systematic reviews and meta-analysis are required on the effect of IVB and MPC combination in cases of DME.
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